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Background: Extensive-stage small-cell lung cancer (SCLC) 
patients who progress after platinum-based chemotherapy are tra-
ditionally categorized as platinum sensitive (progression ≥ 90 days 
from last platinum dose) or refractory (progression < 90 days), a 
practice arising from seminal observations of worse survival in 
refractory patients. Subsequent trials accounted for platinum sensi-
tivity, resulting in higher sample sizes and increased resource use.
Methods: To assess whether platinum-sensitivity status remains associ-
ated with outcomes, patient-level data from recent Southwest Oncology 
Group trials in second- and/or third-line extensive-stage SCLC were 
pooled. Hazard ratios (HRs) for progression-free survival (PFS) and 
overall survival (OS) accounting for platinum sensitivity were calcu-
lated using unadjusted and adjusted Cox Proportional Hazard models. 
Recursive partitioning was performed to define prognostic risk groups.
Results: Of 329 patients, 151 were platinum sensitive and 178 refrac-
tory. HRs from unadjusted Cox PFS and OS models for refractory 
versus sensitive disease were 1.0 (95% confidence interval, 0.81–
1.25; p = 0.98) and 1.24 (0.99–1.57; p = 0.06), respectively. Adjusted 
Cox models showed that only elevated serum lactate dehydrogenase 
(HR, 2.04; p < 0.001), males (HR, 1.36; p = 0.04), performance status 
of 1 (HR, 1.25; p = 0.02), and weight loss greater than or equal to 5% 
(1.53, p = 0.01) were independently associated with OS. Platinum-
sensitivity status was not associated with PFS (HR, 1.11; p = 0.49) or 
OS (HR, 1.25; p = 0.14), except in a model that excluded 36 patients 
who received more than one prior chemotherapy regimen (HR, 1.34; 
p = 0.049). Prognostic groups with differential OS outcomes (high, 
intermediate, and poor risk) were identified.
Conclusions: Platinum-sensitivity status may no longer be strongly 
associated with PFS or OS in at least one multivariate model. Validation 
of prognostic risk groups identified here is warranted. These data have 
critical implications in the design of future SCLC trials.
Key Words: Small-cell lung cancer, Platinum sensitive, Platinum 
refractory, Clinical trials, Treatment, Southwest Oncology Group.
(J Thorac Oncol. 2015;10: 110–115)
Disease progression after initial platinum-based che-motherapy is almost universal in patients with exten-
sive-stage small-cell lung cancer (SCLC).1 At the time of 
progression, patients have traditionally been categorized as 
either platinum sensitive (defined as progression > 90 days 
from last platinum dose) or platinum refractory (progression < 
90 days from last platinum dose). Patients who progress while 
receiving platinum-based therapy are sometimes labeled as 
“platinum resistant”; however, many clinicians likewise define 
these patients as “platinum refractory” as well.
The practice of categorizing patients according to plat-
inum-sensitivity status arose from observations in a phase II 
trial of the investigational cytotoxic agent teniposide.2 In this 
trial that accrued 50 previously-treated SCLC patients, longer 
time from prior chemotherapy discontinuation (i.e., >2.6 mo) 
and response to prior chemotherapy were found to be associ-
ated with response to subsequent teniposide.
Since those seminal observations, subsequent efficacy 
trials in SCLC began accounting for platinum-sensitivity 
status. In many cases, this resulted in more complex studies, 
higher sample sizes and increased resource use. Some studies 
opted to solely focus on the platinum-sensitive group, exclud-
ing those with refractory disease.3,4 In Southwest Oncology 
Group (SWOG), trials in previously treated SCLC since 2000 
have mandated independent accrual to platinum-sensitive and 
platinum-refractory strata to account for the possibility of dif-
ferential outcomes to investigational therapies between these 
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groups. However, recent trials (both SWOG and non-SWOG) 
have not shown divergent outcomes related to platinum-sen-
sitivity status.5–9
In the past decade, SWOG has conducted three phase 
II trials of investigational regimens in platinum-treated SCLC 
(S0802, S0435, and S0327); these trials are summarized in 
Table 1.5–7 In these studies, progression-free survival (PFS) 
and overall survival (OS) were generally comparable between 
platinum-sensitive and platinum-refractory strata across all 
trials, except for S0802 where modest advantage for PFS 
and OS in the aflibercept-containing arm was demonstrated. 
Similarly, the final results of a recent non-SWOG phase II trial 
of temozolomide in platinum-treated SCLC also showed no 
clear differences in outcomes dependent on platinum-sensi-
tivity status.10 We therefore sought to evaluate the association 
between platinum-sensitivity status and SCLC patient out-
come in the modern era using the pooled SWOG database.
METHODS
Updated patient-level data from S0802, S0435, and 
S0327 were pooled. S0802 randomized patients to either topo-
tecan alone or topotecan plus the angiogenesis inhibitor afliber-
cept (vascular endothelial growth factor [VEGF]-Trap). S0435 
was a single arm trial of the vascular endothelial growth factor 
tyrosine kinase inhibitor (VEGFR-TKI) sorafenib. S0327 was 
a single arm trial of the proteasome inhibitor PS-341 (bort-
ezomib). Each of the trials had consistent eligibility criteria 
and collected the same baseline demographic variables. The 
primary endpoint for S0802 was 3-month PFS, whereas the 
primary endpoint for S0435 and S0327 was response rate. All 
staging definitions used by SWOG for these trials preceded the 
7th edition of the tumor, node, metastasis staging system. All 
studies were reviewed and approved by Institutional Review 
Boards and all patients gave written informed consent.
Multivariate Cox regression models were fit to assess 
the relationship between baseline characteristics and PFS and 
OS. PFS and OS estimates were calculated using the method 
of Kaplan–Meier. Confidence intervals for the median were 
constructed using the method of Brookmeyer–Crowley. All p 
values were two-sided. To investigate a predictive model for 
OS, recursive partitioning was performed using the likelihood 
tree model of LeBlanc and Crowley.11 The minimum node size 
was set at 20.
OS was defined as the duration from the date of enroll-
ment to the date of death due to any cause. Patients last known 
to be alive were censored at the date of last contact. PFS was 
defined as the duration from the date of enrollment to the date 
of first documentation of disease progression, as defined by 
Response Evaluation Criteria in Solid Tumors, symptomatic 
deterioration without documented disease progression, or 
death due to any cause. Patients last known to be alive and 
without evidence of disease progression or symptomatic dete-
rioration were censored at the date of last contact. Disease 
assessments were performed every 6 weeks in all three 
protocols.
RESULTS
Three hundred twenty-nine patients constituted the 
pooled study population. Patient characteristics stratified by 
platinum-sensitivity status are summarized in Table 2. Of 329 
patients, 151 were categorized as platinum sensitive and 178 
were platinum refractory. Median age was 63 years. Males 
comprised 52% of the group while those with performance 
status one constituted 67%. There were 89 patients (28%) with 
clinically significant weight loss of greater than or equal to 5% 
within the preceding 3 months. Elevated lactate dehydroge-
nase (LDH) levels were seen in 43%.
Crude unadjusted analysis of PFS and OS stratified by 
platinum-sensitivity status are summarized in Figure 1. The 
hazard ratio (HR) for PFS (refractory/sensitive) was 1.0 (95% 
confidence interval [CI], 0.81–1.25), with a p value of 0.98. 
The HR for OS (refractory/sensitive) was 1.24 (95% CI, 0.99–
1.57), with a p value of 0.06.
Multivariate analysis of baseline clinical variables and 
PFS (Table 3) showed that only elevated LDH (HR, 1.83; p < 
0.0001) and trial assignment to S0802 (HR, 1.82; p = 0.001) 
were independently prognostic for PFS. In contrast, platinum-
sensitivity status was not associated with PFS. Multivariate 
analysis for OS (Table 4) showed that platinum-sensitivity 
status was also not associated with OS (HR, 1.25; p = 0.14). 
Instead, elevated LDH (HR, 2.04; p < 0.0001), weight loss 
(HR, 1.53; p = 0.01), performance status of one (HR, 1.43; 
p = 0.02), and male sex (HR, 1.36; p = 0.04) were found to 
be the only clinical variables associated with worse OS. In a 
subsequent analysis, 14 patients (six from S0435 and eight 
from S0802) had their prior chemotherapy status changed 
from two or more to exactly one. An additional three patients 
(two on S0435 and one on S0802) who had missing data were 
assumed to have received exactly one prior chemotherapy 
regimen. (The eligibility criteria stated that these patients 
must have received exactly one prior regimen when all 17 of 
these patients were enrolled.) When these 17 patients who 
had exactly one prior chemotherapy were reclassified, mul-
tivariate analysis subsequently showed that prior chemo-
therapy was significantly associated with improved OS (HR, 
0.29; p = 0.03). Sex, LDH, weight loss, and performance 
TABLE 1.  Recent Phase II SWOG Trials in Extensive-Stage Small-Cell Lung Cancer
SWOG Study Regimen No. of Patients Performance Status Allowed No. of Prior Regimens Allowed
S0327 Bortezomib 57 0–1 ≥1
S0435 Sorafenib 83 0–1 1a
S0802 Topotecan ± aflibercept 189 0–1 1
aS0435 was amended to restrict the study population to patients having received only one prior regimen after it had enrolled 22 patients.
SWOG, Southwest Oncology Group.
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TABLE 2.  Patient Characteristics (Stratified by Platinum-Sensitivity Status)
Variables
Overall (n = 329)
Platinum Refractory (n = 178) Platinum Sensitive (n = 151)
Age, median (range) 61 (22–85) 64 (33–85)
Age, ≥65 yr 70 39% 73 48%
Male sex 102 57% 68 45%
Performance status
  0 53 30% 56 37%
  1 124 70% 94 63%
Smoking status
  Never smoker 2 1% 1 1%
  Former smoker 83 47% 76 50%
  Current smoker 64 36% 45 30%
  Smoking status not reported 29 16% 29 19%
Weight loss, ≥5%a 50 29% 39 27%
Elevated LDHa 70 46% 52 39%
Two or more prior chemotherapy regimensa 20 11% 16 11%
Prior RT 122 69% 132 87%
aPercentages are out of the number of patients with nonmissing data.
LDH, lactate dehydrogenase; RT, radiation therapy.
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FIGURE 1.  Kaplan–Meier curves for 
crude progression-free and overall 
survival, stratified by platinum-sensitivity 
status (unadjusted for clinical variables).
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status remained significantly associated with OS; however, 
the rest of the variables (including platinum-sensitivity status) 
remained not to be significantly associated with OS. We then 
analyzed the data excluding the remaining 36 patients who 
received more than one prior chemotherapy regimen. In this 
analysis, platinum-refractory status becomes associated with 
OS (HR, 1.35; 95% CI, 1.00–1.82; p = 0.049). There were no 
substantial changes seen in the PFS multivariate model.
Recursive partitioning analysis showed that specific sub-
sets of patients had differential outcomes dependent on the 
distribution of baseline clinical variables (Fig. 2). Prognostic 
groups consisting of low, intermediate, and high risk subsets 
were identified based on differential median OS outcomes of 
8, 5, and 2.4 months, respectively (Fig. 3), using elevated LDH, 
greater than or equal to 5% weight loss, performance status of 
one, and male sex as risk factors. Specifically, high risk patients 
had two risk factors (elevated LDH and either ≥5% weight loss 
or Zubrod performance status >0), intermediate risk patients 
had one risk factor (either male sex or elevated LDH if not 
already in high risk group), and low risk patients had no risk 
factors (i.e., they had normal LDH and were female). A practi-
cal model for identifying these subjects is provided in Table 5, 
representing a modern classifier that no longer includes plati-
num-sensitivity status as a prognostic indicator.
DISCUSSION
In this modern SWOG database analysis, platinum-sensi-
tivity status was not significantly associated with survival from 
the time of postplatinum progression. However, in an unplanned 
analysis that excluded 36 patients who received more than one 
prior chemotherapy regimen, platinum-sensitivity status was 
found to be associated with OS. Nevertheless, factors prognos-
tic for survival in this pooled analysis included elevated LDH, 
weight loss, poor performance status, and male sex.
These results are divergent from prior studies in this 
context12 and particularly, from the recent results of a ran-
domized study comparing amrubicin with topotecan in 
which 637 relapsed SCLC patients were randomized 2:1 to 
either amrubicin or topotecan.13 The top-line results of that 
trial showed that despite a higher response rate in the amru-
bicin arm (31% versus 17%, p = 0.0002), there was no appar-
ent difference in OS (HR, 0.88; p = 0.17). Nonetheless, there 
was an apparent divergence in OS dependent on platinum-
refractory status. There were 342 patients in the “sensitive 
group” compared to 295 patients in the “refractory group.” 
The former group had better median OS (9.2 mo for amru-
bicin arm; 10 mo for the topotecan arm) when compared to 
the latter group (6.2 mo in the amrubicin arm, 5.7 mo for the 
topotecan arm).
TABLE 3.  Multivariable Analysis of Progression-Free Survival
Clinical Variable Hazard Ratio 95% Confidence Interval p Value
Platinum refractory 1.11 0.83 1.49 0.49
Age, ≥65 yr 1.07 0.80 1.43 0.63
Performance status = 1 1.33 0.99 1.77 0.06
Current smoker vs. former or never 0.90 0.67 1.22 0.51
Male sex 1.14 0.87 1.51 0.35
Elevated LDH 1.83 1.37 2.43 <0.0001
Two or more prior chemotherapy regimens vs. only one 0.87 0.51 1.47 0.59
Weight loss, ≥5% 1.09 0.80 1.48 0.59
Prior radiation therapy 1.22 0.87 1.70 0.26
S0802 vs. S0435 or S0327 1.82 1.29 2.55 0.001
LDH, lactate dehydrogenase.
TABLE 4.  Multivariable Analysis for Overall Survival
Parameter Hazard Ratio 95% Confidence Interval p Value
Platinum refractory 1.25 0.93 1.69 0.14
Age, ≥65 yr 1.06 0.78 1.43 0.72
Performance status = 1 1.43 1.05 1.94 0.02
Current smoker vs. former or never 1.05 0.77 1.43 0.77
Male sex 1.36 1.01 1.83 0.04
Elevated LDH 2.04 1.52 2.76 <0.0001
Two or more prior chemotherapy regimens vs. only one 0.79 0.44 1.40 0.42
Weight loss, ≥5% 1.53 1.11 2.12 0.01
Prior radiation therapy 0.89 0.64 1.25 0.51
S0802 vs. S0435 or S0327 1.28 0.90 1.81 0.17
LDH, lactate dehydrogenase.
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The lack of more contemporary consensus information 
on the value of prospectively stratifying SCLC patients with 
relapsed disease according platinum-refractory status suggests 
that this practice ought to be revisited, particularly with regard 
to phase II drug development. In this context, new agent devel-
opment often relies on intermediate endpoints such as response 
rate or PFS to determine whether to proceed to phase III. As 
reported here, the various phase II agents employed in each of 
the trials did not yield differential outcomes according to pre-
specified strata based on platinum sensitivity, showing that this 
differentiation has limited prognostic significance (i.e., where 
survival outcomes are independent of treatment received). A 
priori, we would have expected to see PFS and OS differences 
based on historical data on platinum-sensitivity status.
Given the failure of platinum-refractory status to pro-
vide statistically significant prognostic information in this 
study, we attempted to develop a new prognostic model based 
on the best available information from the SWOG database. 
If validated in an independent pooled dataset containing the 
same clinical variables described herein, the resulting model 
will have potential relevance for clinical practice and trial 
design. We identified clinically relevant prognostic risk groups 
by recursive partitioning analysis that stratified patients into 
low, intermediate, and high risk groups based on expected 
OS outcomes. These risk groupings are potentially useful for 
individualized patient counseling in clinic and perhaps strati-
fication of patients in prospective phase II trials while remain-
ing agnostic to platinum-sensitivity status. However, it will be 
FIGURE 2.  Recursive partitioning 
analysis of platinum-treated small-cell 
lung cancer. LDH, lactate dehydroge-
nase; OS, overall survival.
FIGURE 3.  Kaplan Meier survival 
curves for high, intermediate, and 
poor risk groups.
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necessary to perform a validation study of these risk group-
ings in an independent SCLC dataset before wide use.
This pooled study is limited by its retrospective nature 
and the heterogeneity of investigational therapies employed 
in the individual trials. We acknowledge the trials included in 
this analysis had no or little activity in this disease; therefore, 
we cannot rule out the possibility that platinum-sensitivity sta-
tus may influence outcome in the context of active therapies. It 
must be emphasized that this study focused solely on the prog-
nostic value of platinum sensitivity (again, independent of 
treatment received) and not its predictive value. Nonetheless, 
the therapeutic effect identified in each of the trials was absent 
or small, reducing the likelihood that an interaction between 
platinum-refractory status and treatment could have biased 
our results. In addition, we lack molecular characterization of 
the tumors that may be needed to develop a robust prognostic 
system. The strengths of this analysis include the consistent 
collection of relevant baseline variables, its relatively robust 
sample size, and the relative homogeneity of protocol design 
inherent in SWOG trials.
CONCLUSIONS
In this modern SCLC database, platinum-sensitivity status 
may no longer be as strongly associated with PFS and/or OS, 
calling into question its use in future prospective trials in exten-
sive-stage SCLC. Baseline performance status, sex, LDH, and 
weight loss remain the only independent prognostic indicators 
of OS outcomes. Here we developed a simple prognostic scor-
ing system from these data that, if validated, would better define 
prognostic subgroups in the clinic and in future studies.
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Intermediate risk (one factor) Elevated LDH (and not high risk) Or Male
Low risk (zero factor) Normal LDH And Female
LDH and sex were the only variables that define the intermediate- and low-risk categories.
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